Sept. 27, 2019–DiaSorin Molecular received the CE mark for its Simplexa VZV Swab Direct assay. The molecular diagnostic test enables the direct detection of varicella-zoster virus DNA from cutaneous and mucocutaneous swab specimens.
“We are committed to expanding our menu of high-quality assays that can be used with our Liaison MDX platform,” Michelle Tabb, chief scientific officer at DiaSorin Molecular, said in a company press release. “Customers are looking to consolidate the testing platforms in their labs. The workflow efficiencies we deliver and our rapidly growing test menu make our platform increasingly attractive and in demand.”
The assay complements the company’s Simplexa HSV 1 & 2 Direct kit. DiaSorin has submitted the Simplexa VZV Swab assay to the FDA for 510(k) clearance.